24.99
+1.69(+7.25%)
Currency In USD
| Previous Close | 23.3 |
| Open | 22.75 |
| Day High | 25 |
| Day Low | 22.51 |
| 52-Week High | 38.33 |
| 52-Week Low | 2.01 |
| Volume | 19,066 |
| Average Volume | 1.15M |
| Market Cap | 39.92M |
| PE | -2.06 |
| EPS | -12.11 |
| Moving Average 50 Days | 22.06 |
| Moving Average 200 Days | 8.56 |
| Change | 1.69 |
If you invested $1000 in Galecto, Inc. (GLTO) since IPO date, it would be worth $66.64 as of January 15, 2026 at a share price of $24.99. Whereas If you bought $1000 worth of Galecto, Inc. (GLTO) shares 5 years ago, it would be worth $79.84 as of January 15, 2026 at a share price of $24.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administrationRecent addition
Galecto Announces Key Additions to Leadership Team
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
Deep hematology/oncology drug development experience added with the appointment of Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Dec 16, 2025 10:00 PM GMT
BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the “Company” or “Galecto”) (Nasdaq: GLTO) today announced that the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 312,535 shares of the Company’s